For Investors

• Analyst Coverage
• Annual Reports
• Calendar
• Contact Investor Relations
• Financial Reports
• Frequently Asked Questions
• Management and Investor Relations
• Media Coverage
• News Releases
• Presentations
• Request Documents
• SEDAR Filings
• Stock Quote
• Webcasts
• Why Invest?

News Releases ::

• Isotechnika announces first sale of commercial supply of voclosporin
  More...October 6, 2008
  
• Isotechnika selected to present at international transplantation conference
  More...September 24, 2008
  
• Isotechnika hires advisors to advance strategic alternatives
  More...August 27, 2008
  

Media Coverage ::

• Isotechnika reports positive Phase 2b trial of voclosporin kidney-transplant drug
  More...May 27, 2008
• Voclosporin reduces plaques, has fewer side effects than cyclosporine
  More...May 5, 2008
• Voclosporin (ISA247) psoriasis trial shows impressive results
  More...April 18, 2008

Media Coverage

• May 27, 2008
  Isotechnika reports positive Phase 2b trial of voclosporin kidney-transplant drug
  The Canadian Press
• May 5, 2008
  Voclosporin reduces plaques, has fewer side effects than cyclosporine
  National Review of Medicine
• April 18, 2008
  Voclosporin (ISA247) psoriasis trial shows impressive results
  Psoriasis Cure Now
• April 18, 2008
  New treatment for psoriasis offers hope of fewer side effects
  OnMedica News
• April 18, 2008
  New Psoriasis Pill Appears Effective
  HealthDay
• April 18, 2008
  Promising Phase III data for Isotechnika's psoriasis drug
  PharmaTimes
• April 17, 2008
  A new drug tested against psoriasis
  Agence France-Presse, Paris
• April 17, 2008
  Researchers find immune drug safely treats psoriasis
  Reuters
• August 8, 2007
  Drug wins fast-track status
  Edmonton Journal
• August 3, 2007
  Isotechnika drug use extended
  Edmonton Journal